Geneva, Switzerland

Yves Guyon-Gellin

This inventor holds 4 USPTO granted patents. Top assignees: Symphar S.a., Ilex Products, Inc., Smithkline Beecham Corporation. Active years: 1987-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yves Guyon-Gellin. Retrieved from https://idiyas.com/inventor/yves-guyon-gellin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.4

ph-index = 2

Forward Citations = 19(Granted Patents)


Location History:

  • Annemasse, FR (1987 - 1995)
  • Geneva, CH (2000 - 2003)

Company Filing History:


Years Active: 1987-2003

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Yves Guyon-Gellin: Innovator in Pharmaceutical Compositions

Introduction

Yves Guyon-Gellin is a notable inventor based in Geneva, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications.

Latest Patents

Yves Guyon-Gellin holds four patents, with his latest focusing on compounds and pharmaceutical compositions containing aminophosphonates that are alpha substituted by phenol groups. These compounds have been shown to possess lipoprotein(a) lowering activity, highlighting their potential in treating cardiovascular conditions.

Career Highlights

Throughout his career, Yves has worked with prominent companies in the pharmaceutical industry, including Symphar S.A. and SmithKline Beecham Corporation. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.

Collaborations

Yves has collaborated with several professionals in his field, including Craig Leigh Bentzen and Hieu Trung Phan. These partnerships have fostered innovation and the sharing of knowledge in pharmaceutical research.

Conclusion

Yves Guyon-Gellin's contributions to pharmaceutical inventions and his collaborative efforts with industry professionals underscore his impact on the field. His work continues to influence the development of effective therapeutic compounds.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…